DSM Commences Tender Offer for Martek Biosciences Corporation
(Thomson Reuters ONE) -
Royal DSM N.V. (NYSE Euronext: DSM KON), the global Life Sciences and Materials
Sciences company headquartered in the Netherlands, today announces that its
indirect wholly-owned subsidiary, Greenback Acquisition Corporation, has
commenced its tender offer for all outstanding shares of common stock of Martek
Biosciences Corporation (NASDAQ: MATK) at a price of $31.50 per share.
The tender offer is being made in connection with the Agreement and Plan of
Merger, dated as of 20 December 2010, by and among DSM, Greenback Acquisition
Corporation and Martek, which DSM and Martek announced on 21 December 2010.
The Martek board of directors has unanimously determined that, among other
things, the offer is fair to and in the best interests of Martek's stockholders
and unanimously recommends that Martek's stockholders accept the offer and
tender their shares.
The tender offer is scheduled to expire at 5:00 p.m. (New York City time) on
Friday, 18 February 2011, unless the offer is extended.
Complete terms and conditions of the tender offer are set forth in the Offer to
Purchase, Letter of Transmittal and other related materials that will be filed
by DSM and Greenback Acquisition Corporation with the SEC on 13 January 2011. In
addition, on 13 January 2011, Martek will file a Solicitation/Recommendation
Statement on Schedule 14D-9 with the SEC relating to the offer.
Copies of the Offer to Purchase, Letter of Transmittal and other related
materials are available free of charge from MacKenzie Partners, Inc., the
information agent for the tender offer, toll-free at (800) 322-2885. The dealer
manager for the tender offer is J.P. Morgan Securities LLC. Citibank, N.A. is
acting as depositary for the tender offer.
DSM - the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance.
Its end markets include human and animal nutrition and health, personal care,
pharmaceuticals, automotive, coatings and paint, electrical and electronics,
life protection and housing. DSM manages its business with a focus on the triple
bottom line of economic performance, environmental quality and social
responsibility, which it pursues simultaneously and in parallel. DSM has annual
net sales of about ?8 billion and employs some 22,700 people worldwide. The
company is headquartered in the Netherlands, with locations on five continents.
DSM is listed on Euronext Amsterdam. More information: www.dsm.com.
Martek
Martek is a leader in the innovation, development, production and sale of high-
value products from microbial sources that promote health and wellness through
nutrition. Martek's technology platform consists of its core expertise, broad
experience and proprietary technology in areas such as microbial biology, algal
genomics, fermentation and downstream processing. This technology platform has
resulted in Martek's development of a number of products, including the
company's flagship product, life'sDHA(TM), a sustainable and vegetarian source
of algal DHA (docosahexaenoic acid) important for brain, heart and eye health
throughout life for use in infant formula, pregnancy and nursing products, foods
and beverages, dietary supplements and animal feeds. Martek also
produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in
infant formula and growing-up milks. Martek's subsidiary, Amerifit Brands,
develops, markets and distributes branded consumer health and wellness products
and holds leading brand positions in all of its key product categories. Amerifit
products are sold in most major mass, club, drug, grocery and specialty stores
and include: Culturelle(®), a leading probiotic supplement; AZO, the leading OTC
brand addressing symptom relief and detection of urinary tract infections; and
Estroven(®), the leading all-natural nutritional supplement brand addressing the
symptoms of menopause.
For more information on Martek Biosciences, visit www.martek.com. For a complete
list of life'sDHA(TM) and life'sARA(TM) products, visit www.lifesdha.com. For
more information about Amerifit Brands, visit www.amerifit.com.
For more information:
DSM Corporate Communications DSM Investor Relations
Herman Betten Hans Vossen
tel. +31 (0) 45 5782017 tel. +31 (0) 45 5782864
fax +31 (0) 45 5740680 fax +31 (0) 10 4590275
e-mailinvestor.relations(at)dsm.com
e-mail media.relations(at)dsm.com
Brunswick Group
Brunswick Group
Kate Miller/Jonathan Glass
Jennifer Lowney/Justin Dini
Tel +44 20 7396 3544
Tel +1 212 333 3810
e-mail dsm(at)brunswickgroup.com
e-mail dsm(at)brunswickgroup.com
Press release-pdf:
http://hugin.info/130663/R/1479373/415068.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DSM N.V. via Thomson Reuters ONE
[HUG#1479373]
Unternehmensinformation / Kurzprofil:
Datum: 13.01.2011 - 08:15 Uhr
Sprache: Deutsch
News-ID 50414
Anzahl Zeichen: 6331
contact information:
Town:
Heerlen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 184 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DSM Commences Tender Offer for Martek Biosciences Corporation"
steht unter der journalistisch-redaktionellen Verantwortung von
DSM N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
